Jazz Pharmaceuticals PLC $JAZZ Stock: Sumitomo Mitsui Trust Group Inc. Increases Holdings

Key Points

• Sumitomo Mitsui Trust Group increased its Jazz Pharmaceuticals stake 71.4% in the third quarter, to 11,605 shares valued at about $2.69 million. Institutional investors collectively own 89.14% of the company.
• Jazz reported quarterly revenue of $1.24 billion, above the roughly $1.21 billion consensus, with sales up 10.4% year over year. The company also raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion.
• Analysts’ consensus rating is Moderate Buy, with an average price target of $293.45. Company insiders have also sold shares recently, including transactions under pre-arranged trading plans.

Sumitomo Mitsui Trust Group Inc. raised its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 71.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 11,605 shares of the specialty pharmaceutical company's stock after buying an additional 4,835 shares during the quarter. Sumitomo Mitsui Trust Group Inc.'s holdings in Jazz Pharmaceuticals were worth $2,687,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in JAZZ. Mirae Asset Global Investments Co. Ltd. bought a new position in Jazz Pharmaceuticals during the 3rd quarter worth about $768,000. Profund Advisors LLC boosted its holdings in Jazz Pharmaceuticals by 208.0% during the third quarter. Profund Advisors LLC now owns 7,783 shares of the specialty pharmaceutical company's stock worth $1,802,000 after purchasing an additional 5,256 shares during the last quarter. ProShare Advisors LLC boosted its holdings in Jazz Pharmaceuticals by 4.1% during the third quarter. ProShare Advisors LLC now owns 4,718 shares of the specialty pharmaceutical company's stock worth $1,092,000 after purchasing an additional 185 shares during the last quarter. Vise Technologies Inc. grew its position in Jazz Pharmaceuticals by 5.3% in the third quarter. Vise Technologies Inc. now owns 2,448 shares of the specialty pharmaceutical company's stock valued at $567,000 after purchasing an additional 123 shares in the last quarter. Finally, State of Wyoming grew its position in Jazz Pharmaceuticals by 191.3% in the third quarter. State of Wyoming now owns 2,534 shares of the specialty pharmaceutical company's stock valued at $587,000 after purchasing an additional 1,664 shares in the last quarter. Institutional investors own 89.14% of the company's stock.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat quarterly estimates, reporting $1.24 billion in revenue versus roughly $1.21 billion expected, with revenue up 10.4% year over year. Coverage also reported that the company raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, helping reinforce the growth outlook. Q3 results and outlook
• Positive Sentiment: RBC, Barclays, Morgan Stanley and JPMorgan issued favorable commentary or raised price targets after the results. The analyst optimism adds support to the stock’s post-earnings momentum. Barclays price-target update
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares under a pre-arranged Rule 10b5-1 plan and retained 140,394 shares. Director Bruce Cozadd also sold 6,000 shares under a pre-arranged plan, while CAO Patricia Carr sold 1,413 shares and retained 6,512. These sales may draw investor attention, but planned transactions are not necessarily a signal about near-term business prospects. Insider transaction coverage

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Canaccord Genuity Group set a $300.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, August 26th. The Goldman Sachs Group assumed coverage on shares of Jazz Pharmaceuticals in a research note on Thursday, September 24th. They set a "buy" rating and a $337.00 price objective for the company. Piper Sandler raised their price objective on Jazz Pharmaceuticals from $301.00 to $310.00 and gave the company an "overweight" rating in a report on Tuesday, August 4th. Wells Fargo & Company raised their price objective on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an "overweight" rating in a report on Tuesday, August 4th. Finally, Weiss Ratings lowered Jazz Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a report on Wednesday, October 28th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $293.45.

Insiders Place Their Bets

In other news, CAO Patricia Carr sold 1,413 shares of the business's stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $231.36, for a total transaction of $326,911.68. Following the sale, the chief accounting officer directly owned 6,512 shares in the company, valued at approximately $1,506,616.32. The trade was a 17.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Robert Iannone sold 76,921 shares of the company's stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $249.70, for a total value of $19,207,173.70. Following the completion of the transaction, the executive vice president directly owned 65,686 shares of the company's stock, valued at $16,401,794.20. This represents a 53.94% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 102,534 shares of company stock worth $25,185,243. Company insiders own 4.10% of the company's stock.

Jazz Pharmaceuticals Trading Up 3.3%

Shares of NASDAQ:JAZZ opened at $234.76 on Friday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.82 and a quick ratio of 1.58. Jazz Pharmaceuticals PLC has a 1 year low of $128.80 and a 1 year high of $266.38. The company has a market capitalization of $15.07 billion, a P/E ratio of 79.85, a P/E/G ratio of 0.44 and a beta of 0.38. The business's 50 day simple moving average is $229.39 and its 200 day simple moving average is $217.74.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, beating the consensus estimate of ($4.03) by $0.15. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.21 billion. During the same period in the previous year, the business earned $8.13 earnings per share. The company's revenue was up 10.4% on a year-over-year basis. On average, research analysts anticipate that Jazz Pharmaceuticals PLC will post 11.08 EPS for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets.

Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

Jazz expanded its portfolio through acquisitions, including the 2021 acquisition of GW Pharmaceuticals, which added Epidiolex and other cannabinoid-based medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.